PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2015 | 1 | 1 |
Tytuł artykułu

Purine nucleoside analogs in the therapy of cancer and neuroinflammation

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Purine nucleoside analogs have been in clinical use for almost 50 years. At the beginning developed as antiviral agents, later their efficacy was demonstrated in cancer treatment, especially hematological malignances. The approval of new purine nucleoside analogs by US Food and Drug Administration (FDA) over the past decade implies that the interest for these drugs still exists. Here, we review new nucleoside analogs that are currently in preclinical or clinical development as anticancer agents. In addition, we highlight the potential for implementation of these drugs in other pathological conditions, particularly in neuroinflammation.
Wydawca

Rocznik
Tom
1
Numer
1
Opis fizyczny
Daty
otrzymano
2015-03-27
zaakceptowano
2015-05-11
online
2015-06-04
Twórcy
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Serbian Academy of Sciences and Arts, KnezMihailova
    35, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
  • Institute for Biological
    Research, Department of Neurobiology, University of
    Belgrade,BulevarDespotaStefana 142, Belgrade, Serbia
Bibliografia
  • [1] Bobrovnikova-Marjon E., Hurov J.B., Targeting metabolicchanges in cancer: novel therapeutic approaches,Annu. Rev.Med., 2014, 65, 157-170.[Crossref]
  • [2] Farber S., Diamond L.K., Temporary remissions in acuteleukemia in children produced by folic acid antagonist,4-aminopteroyl-glutamic acid,N. Engl. J. Med., 1948, 238,787-793.
  • [3] Jordheim L.P., Durantel D., Zoulim F., Dumontet C., Advancesin the development of nucleoside and nucleotide analoguesfor cancer and viral diseases,Nat. Rev. Drug Discov., 2013, 12,447-464.[Crossref]
  • [4] Elion G.B., The purine path to chemotherapy, Science, 1989,244, 41-47.
  • [5] Elion G.B., Hitchings G.H., Antagonist of nucleic acidderivatives. III. The specificity of the purine requirement ofLactobacillus casei,J. Biol. Chem., 1950, 185, 651-655.
  • [6] Hitchings G.H., Antagonists of nucleic acid derivatives asmedicinal agents,Annu. Rev. Pharmacol. Toxicol., 1992, 32, 1-6.[Crossref]
  • [7] Silverstein P.S., KumarS., KumarA., HIV-1, HCV and alcoholin the CNS: potential interactions and effects on neuroinflammation,Curr. HIV Res.,2014, 12, 282-292.
  • [8] GroverV.P., PaveseN., KohS.B., WylezinskaM., SaxbyB.K.,GerhardA., FortonD.M., BrooksD.J., ThomasH.C., Taylor-RobinsonS.D., Cerebral microglial activation in patients withhepatitis C: in vivo evidence of neuroinflammation, J. Viral.Hepat., 2012, 19, e89-96.[Crossref]
  • [9] ByrnesV., MillerA., LowryD., HillE., WeinsteinC., AlsopD.,LenkinskiR., AfdhalN.H., Effects of anti-viral therapy and HCVclearance on cerebral metabolism and cognition, J. Hepatol.,2012, 56, 549-556.[Crossref]
  • [10] BokemeyerM., DingX.Q., GoldbeckerA., RaabP., HeerenM.,ArvanitisD., Tillmann, H. LanfermannH.L., WeissenbornK.,Evidence for neuroinflammation and neuroprotection in HCVinfection-associated encephalopathy, Gut, 2011, 60, 370-377.[Crossref]
  • [11] NingQ., BrownD., ParodoJ., CattralM., GorczynskiR., ColeE.,FungL., DingJ.W., LiuM.F., RotsteinO., PhillipsM.J., LevyG.,Ribavirin inhibits viral-induced macrophage production ofTNF, IL-1, the procoagulant fgl2 prothrombinase and preservesTh1 cytokine production but inhibits Th2 cytokine response, J.Immunol., 1998, 160, 3487-3493.
  • [12] BarnesE., SalioM., CerundoloV., MedlinJ., MurphyS.,DusheikoG., KlenermanP., Impact of alpha interferonand ribavirin on the function of maturing dendritic cells,Antimicrob. Agents Chemother., 2004, 48, 3382-3389.
  • [13] LanghansB., NischalkeH.D., ArndtS., BraunschweigerI.,NattermannJ., SauerbruchT., SpenglerU., Ribavirin exertsdifferential effects on functions of Cd4+ Th1, Th2, andregulatory T cell clones in hepatitis C,. PLoS One, 2012, 7,e42094.
  • [14] GrygielJ.J., BalisF.M., CollinsJ.M., LesterC.M., PoplackD.G.,Pharmacokinetics of tiazofurin in the plasma and cerebrospinalfluid of rhesus monkeys, Cancer Res., 1985, 45, 2037-2039.
  • [15] JeulinH., VenardV., CarapitoD., FinanceC., KedzierewiczF.,Effective ribavirin concentration in mice brain usingcyclodextrin as a drug carrier: evaluation in a measlesencephalitis model, Antiviral Res., 2009, 81, 261-266.
  • [16] Cano-Soldado P., Pastor-Anglada M., Transporters thattranslocate nucleosides and structural similar drugs: structuralrequirements for substrate recognition,Med. Res. Rev., 2012,32, 428-457.[Crossref]
  • [17] Minuesa G., Huber-Ruano I., Pastor-Anglada M., KoepsellH., Clotet B., Martinez-Picado J., Drug uptake transporters inantiretroviral therapy,Pharmacol. Ther., 2011, 132, 268-279.
  • [18] Ewald B., Sampath D., Plunkett W., Nucleoside analogs:molecular mechanisms signaling cell death, Oncogene, 2008,27, 6522-6537.[Crossref]
  • [19] Chevaliez S., Brillet R., Lazaro E., Hezode C., Pawlotsky J.M.,Analysis of ribavirin mutagenicity in human hepatitis C virusinfection,J. Virol., 2007, 81, 7732-7741.[Crossref]
  • [20] Robak T., Lech-Maranda E., Korycka A., Robak E., Purinenucleoside analogs as immunosuppressive and antineoplasticagents: mechanism of action and clinical activity,Curr. Med.Chem., 2006, 13, 3165-3189.[Crossref]
  • [21] Santana V.M., Hurwitz C.A., Blakley R.L., Crom W.R., Luo X.,Roberts W.M., et al. Complete hematologic remissions inducedby 2-chlorodeoxyadenosine in children with newly diagnosedacute myeloid leukemia, Blood, 1994, 84, 1237-1242.
  • [22] Estey E., Plunkett W., Gandhi V., Rios M.B., Kantarjian H.,Keating M.J.,Fludarabine and arabinosylcytosine therapy ofrefractory and relapsed acute myelogenous leukemia,Leuk.Lymphoma, 1993, 9, 343-350.
  • [23] Barba P., Sampol A., Calbacho M., Gonzalez J., Serrano J.,Martinez-Sanchez P., et al., Clofarabine-based chemotherapyfor relapsed/refractory adult acute lymphoblastic leukemiaand lymphoblastic lymphoma. The Spanish experience,Am. J.Hematol., 2012, 87, 631-634.[Crossref]
  • [24] Krett N.L., Davies K.M., Ayres M., Ma C., Nabhan C., Gandhi V.,et al., 8-amino-adenosine is a potential therapeutic agent formultiple myeloma,Mol. Cancer Ther., 2004, 3, 1411-1420.
  • [25] Frey J.A., Gandhi V., 8-Amino-adenosine inhibits multiplemechanisms of transcription,Mol. Cancer Ther., 2010, 9,236-245.[Crossref]
  • [26] Gandhi V., Ayres M., Halgren R.G., Krett N.L., Newman R.A.,Rosen S.T., 8-chloro-cAMP and 8-chloro-adenosine act by thesame mechanism in multiple myeloma cells, Cancer Res., 2001,61, 5474-5479.
  • [27] Gu Y.Y., Zhang H.Y., Zhang H.J., Li S.Y., Ni J.H., Jia H.T., 8-Chloroadenosineinhibits growth at least partly by interferingwith actin polymerization in cultured human lung cancercells,Biochem. Pharmacol., 2006, 72, 541-550.[Crossref]
  • [28] Yang S.Y., Jia X.Z., Feng L.Y., Li S.Y., An G.S., Ni J.H., etal., Inhibition of topoisomerase II by 8-chloro-adenosinetriphosphate induces DNA double-stranded breaks in 8-chloroadenosine-exposed human myelocytic leukemia K562cells,Biochem. Pharmacol., 2009, 77, 433-443.
  • [29] Cho-Chung YS. Role of cyclic AMP receptor proteins ingrowth, differentiation, and suppression of malignancy: newapproaches to therapy. Cancer Res., 1990, 50, 7093-7100.
  • [30] Halgren R.G., Traynor A.E., Pillay S., Zell J.L., Heller K.F., KrettN.L., et al. 8Cl-cAMP cytotoxicity in both steroid sensitiveand insensitive multiple myeloma cell lines is mediated by8Cl-adenosine, Blood, 1998, 92, 2893-2898.
  • [31] Katsaros D., Tortora G., Tagliaferri P., Clair T., Ally S., Neckers L.,et al. Site-selective cyclic AMP analogs provide a new approachin the control of cancer cell growth, FEBS lett., 1987, 223,97-103.
  • [32] Grbovic O., Jovic V., Ruzdijic S., Pejanovic V., Rakic L., KanazirS., 8-Cl-cAMP affects glioma cell-cycle kinetics and selectivelyinduces apoptosis,Cancer Invest., 2002, 20, 972-982.[Crossref]
  • [33] Jankovic D., Pesic M., Markovic J., Kanazir S., Markovic I.,Rakic L., et al., The combination of sulfinosine and 8-Cl-cAMPinduces synergistic cell growth inhibition of the humanneuroblastoma cell line in vitro,Invest. NewDrugs, 2006, 24,15-25.[Crossref]
  • [34] Pesic M., Podolski A., Rakic L., Ruzdijic S., Purine analogssensitize the multidrug resistant cell line (NCI-H460/R) todoxorubicin and stimulate the cell growth inhibitory effect ofverapamil,Invest. NewDrugs, 2010, 28, 482-492.
  • [35] Roecker A.M., Allison J.C., Kisor D.F., Nelarabine: efficacy inthe treatment of clinical malignancies, Future Oncol., 2006, 2,441-448.[Crossref]
  • [36] Lambe C.U., Averett D.R., Paff M.T., Reardon J.E., Wilson J.G.,Krenitsky T.A., 2-Amino-6-methoxypurine arabinoside: an agentfor T-cell malignancies,Cancer Res., 1995, 55, 3352-3356.
  • [37] Gandhi V., Plunkett W.. Clofarabine and nelarabine: two newpurine nucleoside analogs,Curr. Opin. Oncol., 2006, 18,584-590.[Crossref]
  • [38] Frei P., Biedermann L., Nielsen O.H., Rogler G.. Use ofthiopurines in inflammatory bowel disease,World J. Gastroenterol.,2013, 19, 1040-1048.
  • [39] Snow J.L., Gibson L.E., A pharmacogenetic basis for the safeand effective use of azathioprine and other thiopurine drugsin dermatologic patients,J. Am. Acad. Dermatol., 1995, 32,114-116.[Crossref]
  • [40] Gaffney K., Scott D.G., Azathioprine and cyclophosphamide inthe treatment of rheumatoid arthritis,Br. J. Rheumatol., 1998,37, 824-836.[Crossref]
  • [41] Sanz M.A., Martin G., Lo Coco F., Choice of chemotherapy ininduction, consolidation and maintenance in acute promyelocyticleukaemia,Best Pract. Res. Clin. Haematol., 2003, 16,433-451.[Crossref]
  • [42] Schmiegelow K., Nielsen S.N., Frandsen T.L., NerstingJ.,Mercaptopurine/Methotrexate maintenance therapy ofchildhood acute lymphoblastic leukemia: clinical facts andfiction,J. Pediatr. Hematol.Oncol.,2014, 36, 503-517.[Crossref]
  • [43] Maybaum J., Mandel H.G., Differential chromatid damageinduced by 6-thioguanine in CHO cells,Exp. Cell. Res. 1981, 135,465-468.
  • [44] Swann P.F., Waters T.R., Moulton D.C., Xu Y.Z., Zheng Q.,Edwards M., et al., Role of postreplicative DNA mismatch repairin the cytotoxic action of thioguanine, Science, 1996, 273,1109-1111.
  • [45] Fotoohi A.K., Coulthard S.A., Albertioni F., Thiopurines: factorsinfluencing toxicity and response,Biochem. Pharmacol., 2010,79, 1211-1220.[Crossref]
  • [46] Karran P., Thiopurines, DNA damage, DNA repair and therapyrelatedcancer,Br. Med. Bull., 2006, 79-80, 153-170.
  • [47] Revankar G.R., Hanna N.B., Imamura N., Lewis A.F., LarsonS.B., Finch R.A., et al., Synthesis and in vivo antitumoractivity of 2-amino-9H-purine-6-sulfenamide, -sulfinamide,and -sulfonamide and related purine ribonucleosides,J. Med.Chem., 1990, 33, 121-128.[Crossref]
  • [48] Avery T.L., Finch R.A., Vasquez K.M., Radparvar S., Hanna N.B.,Revankar G.R., et al., Chemotherapeutic characterization inmice of 2-amino-9-beta-D-ribofuranosylpurine-6-sulfinamide(sulfinosine), a novel purine nucleoside with unique antitumorproperties,Cancer Res., 1990, 50, 2625-2630.
  • [49] Ramasamy K., Imamura N., Hanna N.B., Finch R.A., Avery T.L.,Robins R.K., et al., Synthesis and antitumor evaluation inmice of certain 7-deazapurine (pyrrolo[2,3-d]pyrimidine) and3-deazapurine (imidazo[4,5-c]pyridine) nucleosides structurallyrelated to sulfenosine, sulfinosine, and sulfonosine. J. Med.Chem., 1990, 33, 1220-1225.
  • [50] Hanna N.B., Bhattacharya B.K., Robins R.K., Avery T.L.,Revankar G.R., Sulfinosine congeners: synthesis and antitumoractivity in mice of certain N9-alkylpurines and purine ribonucleosides.J. Med. Chem., 1994, 37, 177-183.[Crossref]
  • [51] Fujitaki J.M., Nord L.D., Willis R.C., Cellular metabolism ofthe antitumor nucleoside, sulfinosine, 2-amino-9-(β-Dribofuranosyl)purine-6-sulfinamide, Proc. Am. Assoc. Cancer.Res., 1989, 30, 596.
  • [52] Riley T.A., Finch R.A., Vasquez K.M., Isolation, identification,synthesis and therapeutic evaluation of selected metabolitesof sulfinosine, a novel purine nucleoside analog active againstthiopurine refractory experimental leukemia, Proc. Am. Assoc.Cancer. Res., 1989, 30, 599.
  • [53] Crabtree G.W., Finch R.A., Vasquez K.M., Cysteine andglutathione competition for adduct formation with 2-amino-9-(β-D-ribofuranosyl)purine-6-sulfinamide (sulfinosine, fin)modulates therapeutic efficacy, Proc. Am. Assoc. Cancer. Res.1989, 30, 597.
  • [54] Milosevic J., Kanazir S., Medic-Mijacevic L., Pejanovic V.,Stokic Z., Konjevic G., et al., Sulfinosine-induced cell growthinhibition and apoptosis in human lung carcinomas invitro,Invest. NewDrugs, 2002, 20, 229-240.[Crossref]
  • [55] Dacevic M., Isakovic A., Podolski-Renic A., Isakovic A.M.,Stankovic T., Milosevic Z., et al., Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancerprogression in multi-drug resistant cancer cell lines, PloS One2013, 8, e54044.
  • [56] Pesic M., Markovic J.Z., Jankovic D., Kanazir S., Markovic I.D.,Rakic L., et al., Induced resistance in the human non smallcell lung carcinoma (NCI-H460) cell line in vitro by anticancerdrugs,J. Chemother. 2006, 18, 66-73.
  • [57] Andjelkovic T., Pesic M., Bankovic J., Tanic N., Markovic I.D.,Ruzdijic S., Synergistic effects of the purine analog sulfinosineand curcumin on the multidrug resistant human non-small celllung carcinoma cell line (NCI-H460/R),Cancer Biol. Ther., 2008,7, 1024-1032.
  • [58] Pesic M., Andjelkovic T., Bankovic J., Markovic I.D., Rakic L.,Ruzdijic S., Sulfinosine enhances doxorubicin efficacy throughsynergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R),Invest.NewDrugs 2009, 27, 99-110.
  • [59] Menon S.G., Goswami P.C., A redox cycle within the cell cycle:ring in the old with the new, Oncogene, 2007, 26, 1101-1109.[Crossref]
  • [60] Shu Q., Nair V., Inosine monophosphate dehydrogenase(IMPDH) as a target in drug discovery,Med. Res. Rev. 2008, 28,219-232.[Crossref]
  • [61] Jackson R.C., Weber G., Morris H.P., IMP dehydrogenase, anenzyme linked with proliferation and malignancy, Nature, 1975,256, 331-333.[Crossref]
  • [62] Assouline S., Culjkovic B., Cocolakis E., Rousseau C., Beslu N.,Amri A., et al., Molecular targeting of the oncogene eIF4E inacute myeloid leukemia (AML): a proof-of-principle clinical trialwith ribavirin, Blood, 2009, 114, 257-260.[Crossref]
  • [63] Malek K., Boosalis M.S., Waraska K., Mitchell B.S., WrightD.G., Effects of the IMP-dehydrogenase inhibitor, Tiazofurin,in bcr-abl positive acute myelogenous leukemia. Part I. In vivostudies,Leuk. Res. 2004, 28, 1125-1136.[Crossref]
  • [64] Gharehbaghi K., Burgess G.S., Collart F.R., Litz-JacksonS., Huberman E., Jayaram H.N., et al., p210 bcr-abl confersoverexpression of inosine monophosphate dehydrogenase: anintrinsic pathway to drug resistance mediated by oncogene,Leukemia, 1994, 8, 1257-1263.
  • [65] Assouline S., Culjkovic-Kraljacic B., Bergeron J., Caplan S.,Cocolakis E., Lambert C., et al., A phase I trial of ribavirinand low-dose cytarabine for the treatment of relapsed andrefractory acute myeloid leukemia with elevated eIF4E,Haematologica, 2015, 100, e7-9.[Crossref]
  • [66] Borden K.L., Culjkovic-Kraljacic B., Ribavirin as an anti-cancertherapy: acute myeloid leukemia and beyond?,Leuk.Lymphoma, 2010, 51, 1805-1815.
  • [67] Kentsis A., Topisirovic I., Culjkovic B., Shao L., Borden K.L.,Ribavirin suppresses eIF4E-mediated oncogenic transformationby physical mimicry of the 7-methyl guanosine mRNA cap,Proc.Natl. Acad. Sci. U.S.A., 2004, 101, 18105-18110.
  • [68] Pesic M., Drabek K., Esler C., Ruzdijic S., Pejanovic V.,Pietrzkowski Z., Inhibition of cell growth and proliferation inhuman glioma cells and normal human astrocytes inducedby 8-Cl-cAMP and tiazofurin,Nucleosides Nucleotides NucleicAcids, 2000, 19, 963-975.
  • [69] Drabek K., Pesic M., Piperski V., Ruzdijic S., Medic-Mijacevic L.,Pietrzkowski Z., et al., 8-Cl-cAMP and tiazofurin affect vascularendothelial growth factor production and glial fibrillary acidicprotein expression in human glioblastoma cells,AnticancerDrugs, 2000, 11, 765-770.
  • [70] Witkowski J.T., Robins R.K., Sidwell R.W., Simon L.N., Design,synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides,J.Med. Chem., 1972, 15, 1150-1154.
  • [71] Jin R., Fossler M.J., McHutchison J.G., Howell C.D., DowlingT.C., Population pharmacokinetics and pharmacodynamicsof ribavirin in patients with chronic hepatitis C genotype 1infection,AAPS J., 2012, 14, 571-580.[Crossref]
  • [72] Scotto G., Campanozzi F., D’Adduzio A., Grimaldi M., FazioV., Interferon-alpha (IFN alpha) daily dose versus IFN alphaplus ribavirin for treatment-naive chronic hepatitis c patientsinfected by genotype 1b,BioDrugs, 2003, 17, 281-286.
  • [73] Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., IdeoG., et al., Randomised trial of interferon alpha2b plus ribavirinfor 48 weeks or for 24 weeks versus interferon alpha2b plusplacebo for 48 weeks for treatment of chronic infection withhepatitis C virus. International Hepatitis Interventional TherapyGroup (IHIT), Lancet, 1998, 352, 1426-1432.
  • [74] Chu H.Y., Englund J.A.. Respiratory syncytial virus disease:prevention and treatment,Curr. Top. Microbiol. Immunol., 2013,372, 235-258.
  • [75] Gueller S., Duenzinger U., Wolf T., Ajib S., Mousset S., BergerA., et al., Successful systemic high-dose ribavirin treatmentof respiratory syncytial virus-induced infections occurringpre-engraftment in allogeneic hematopoietic stem celltransplant recipients,Transpl. Infect. Dis., 2013, 15, 435-440.[Crossref]
  • [76] Parker W.B., Metabolism and antiviral activity of ribavirin,VirusRes., 2005, 107, 165-171.[Crossref]
  • [77] Hong Z., Cameron C.E., Pleiotropic mechanisms of ribavirinantiviral activities. Prog. Drug Res., 2002, 59, 41-69.
  • [78] Huggins J.W., Robins R.K., Canonico P.G., Synergistic antiviraleffects of ribavirin and the C-nucleoside analogs tiazofurinand selenazofurin against togaviruses, bunyaviruses, andarenaviruses,Antimicrob. Agents Chemother. 1984, 26,476-480.
  • [79] Colombo G., Lorenzini L., Zironi E., Galligioni V., SonvicoF., Balducci A.G., et al., Brain distribution of ribavirin afterintranasal administration,Antiviral Res., 2011, 92, 408-414.
  • [80] Hosoya M., Mori S., Tomoda A., Mori K., Sawaishi Y., KimuraH., et al., Pharmacokinetics and effects of ribavirin followingintraventricular administration for treatment of subacutesclerosing panencephalitis,Antimicrob. Agents Chemother.,2004, 48, 4631-4635.
  • [81] Solbrig M.V., Schlaberg R., Briese T., Horscroft N., LipkinW.I., Neuroprotection and reduced proliferation of microgliain ribavirin-treated bornavirus-infected rats, AntimicrobialAntimicrob. Agents Chemother., 2002, 46, 2287-2291.
  • [82] Janac B., Pesic V., Veskov R., Ristic S., Tasic J., Piperski V., et al.,The effects of tiazofurin on basal and amphetamine-inducedmotor activity in rats,Pharmacol. Biochem. Behav., 2004, 77,575-582.[Crossref]
  • [83] Allison A.C., Eugui E.M., Mycophenolate mofetil and itsmechanisms of action, Immunopharmacology, 2000, 47,85-118.[Crossref]
  • [84] Jain J., Almquist S.J., Heiser A.D., Shlyakhter D., Leon E.,Memmott C., et al., Characterization of pharmacologicalefficacy of VX-148, a new, potent immunosuppressive inosine5’-monophosphate dehydrogenase inhibitor,J. Pharmacol. Exp.Ther., 2002, 302, 1272-1277.
  • [85] Peavy D.L., Koff W.C., Hyman D.S., Knight V., Inhibition oflymphocyte proliferative responses by ribavirin,Infect. Immun.,1980, 29, 583-589.
  • [86] Milicevic I., Pekovic S., Subasic S., Mostarica-Stojkovic M.,Stosic-Grujicic S., Medic-Mijacevic L., et al., Ribavirin reducesclinical signs and pathological changes of experimentalautoimmune encephalomyelitis in Dark Agouti rats,J. Neurosci.Res., 2003, 72, 268-278.[Crossref]
  • [87] Stosic-Grujicic S., Savic-Radojevic A., Maksimovic-Ivanic D.,Markovic M., Bumbasirevic V., Ramic Z., et al., Down-regulationof experimental allergic encephalomyelitis in DA rats bytiazofurin,J. Neuroimmunol., 2002, 130, 66-77.
  • [88] Lavrnja I., Stojkov D., Bjelobaba I., Pekovic S., Dacic S.,Nedeljkovic N., et al., Ribavirin ameliorates experimentalautoimmune encephalomyelitis in rats and modulates cytokineproduction,Int. Immunopharmacol., 2008, 8, 1282-1290. [Crossref]
  • [89] Yamada Y., Natsumeda Y., Weber G., Action of the activemetabolites of tiazofurin and ribavirin on purified IMPdehydrogenase, Biochemistry, 1988, 27, 2193-2196.[Crossref]
  • [90] Lavrnja I., Stojkov D., Pekovic S., Subasic S., Mostarica-Stojkovic M., Stosic-Grujicic S., et al., Combination ofnucleoside analogues tiazofurin and ribavirin downregulatesexperimental autoimmune encephalomyelitis,Ann. N. Y. Acad.Sci., 2005, 1048, 392-395.
  • [91] Stojkov D., Lavrnja I., Subasic S., Bjelobaba I., Pekovic S.,Gadjanski I., et al., Therapeutic Effect of Nucleoside Analogson Experimental Autoimmune Encephalomyelitis in Dark AgoutiRats, Arch. Biol. Sci. 2006, 58, 13-20.[Crossref]
  • [92] Lavrnja I., Savic D., Bjelobaba I., Dacic S., Bozic I., ParabuckiA., et al., The effect of ribavirin on reactive astrogliosis inexperimental autoimmune encephalomyelitis,J. Pharmacol.Sci., 2012, 119, 221-232.[Crossref]
  • [93] Pekovic S., Filipovic R., Subasic S., Lavrnja I., Stojkov D.,Nedeljkovic N., et al., Downregulation of glial scarringafter brain injury: the effect of purine nucleoside analogueribavirin,Ann. N. Y. Acad. Sci., 2005, 1048, 296-310.
  • [94] Pekovic S., Subasic S., Nedeljkovic N., Bjelobaba I., FillipovicR., Milenkovic I., et al., Molecular basis of brain injury andrepair. In: Ruzdijic S., Rakic Lj. (Eds), Neurobiological Studies- from Genes to Behaviour, Research Signpost, Kerala, India,2006, 143-165.
  • [95] Savic D., Lavrnja I., Dacic S., Bjelobaba I., Nedeljkovic N.,Pekovic S., et al., Combined Treatment with Ribavirin andTiazofurin Attenuates Response of Glial Cells in ExperimentalAutoimmune Encephalomyelitis, Arch. Biol. Sci., 2012, 64,843-850.[Crossref]
  • [96] Savic D., Lavrnja I., Dacic S., Bjelobaba I., Nedeljkovic N.,Stojiljkovic M., et al., Tiazofurin Modulates Lipopolysaccharide-Activated Microglia in Vitro, Arch. Biol. Sci., 2014, 66,1633-1640.[Crossref]
  • [97] Savic D., Stojiljkovic M., Lavrnja I., Parabucki A., BjelobabaI., Nedeljkovic N., et al., Ribavirin shows immunomodulatoryeffects on activated microglia,Immunopharmacol. Immunotoxicol.,2014, 36, 433-441.[Crossref]
  • [98] Vivithanaporn P., Maingat F., Lin L.T., Na H., Richardson C.D.,Agrawal B., et al., Hepatitis C virus core protein inducesneuroimmune activation and potentiates Human ImmunodeficiencyVirus-1 neurotoxicity, PloS One, 2010, 5, e12856.
  • [99] Wilkinson J., Radkowski M., Laskus T., Hepatitis C virusneuroinvasion: identification of infected cells,J. Virol., 2009,83, 1312-1319.[Crossref]
  • [100] Piperski V., Vracar M., Jokanovic M., Stukalov P., Rakic L.,Detection of apoptosis and phagocytosis in vitro in C6 ratglioma cells treated with tiazofurin,Apoptosis, 1998, 3,345-352.[Crossref]
  • [101] Wei J., Gabrusiewicz K., Heimberger A., The controversial roleof microglia in malignant gliomas,Clin. Dev. Immunol., 2013,2013, 285246.
  • [102] Sharma N.K., Mahadevan N., Balakumar P., Adenosinetransport blockade restores attenuated cardioprotectiveeffects of adenosine preconditioning in the isolated diabeticrat heart: potential crosstalk with opioid receptors,Cardiovasc.Toxicol., 2013, 13, 22-32.[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_1515_motth-2015-0002
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.